Ann: Factor Therapeutics Appoints Transaction Advisor, page-22

to me ftt have been running a lean operation, efficiently focussing funds for the trial. as the readout approaches, of course assuming that it is successful they have a lot to do between preparing the submission for the EU, preparing to meet with the FDA, planning phase 3 in US. partnering discussions are yet another item that deserves attention. workIng In R&D I can appreciate tryong to do thIngs as effIcIently as you can, and also the need to IdentIfy chunks you can outsource or draw in contract support.

having a local company means communications are greatly increased. and with factor being interested in us and Europe having a company located in only one of those locations would be suboptimal, eg a us company isn't going to know much about Europe (no offence to any Americans here but the us is very us centric if you know what I mean).